Page 178 - 80_01

Basilio
Colligris,
Jesús
Pintor

20. Management and therapy of dry eye disease: report of the Management and

Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 5(2),

163-78 (2007).

21. Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory

stress on the mouse ocular surface. Eye Contact Lens. 31(5), 186-93 (2005).

22. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of

inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the

ocular surface. Invest Ophthalmol Vis Sci. 45(12), 4293-301 (2004).

23. Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical

corticosteroids on dry eye. J Zhejiang Univ Sci B. 7(8), 675-8 (2006).

24. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies

of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe

dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 107(4), 631-9 (2000).

25. Spies CM, Gaber T, Hahne M, et al. Rimexolone inhibits proliferation, cytokine

expression and signal transduction of human CD4+ T-cells. Immunol Lett. 131(1), 24-

32 (2010).

26. AL-2178. ClinicalTrials.gov Identifier: NCT00471419

http://clinicaltrials.gov/ct2/show/NCT00471419?term=AL-2178+Rimexolone&rank=1.

(2008).

27. Anglade E, Yatscoff R, Foster R, et al. Next-generation calcineurin inhibitors for

ophthalmic indications. Expert Opin Investig Drugs. 16(10), 1525-40 (2007).

28. LX214. ClinicalTrials.gov Identifier: NCT00851734

http://clinicaltrials.gov/ct2/show/NCT00851734?term=LX214&rank=1. (2012).

29. Uckun FM, Malavia R, Sudbeck EA. JAK-3 inhibitors for treating allergic

disorders. US20006080747 (2000)

30. Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus

kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology.

119(7), 1328-35 (2012).

31. Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical

ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye

disease. Ophthalmology. 119(7), e43-50 (2012).

32. Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. Ocul

Surf. 8(1), 18-28 (2010).

33. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-

linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea.

22(2), 97-101 (2003).

34. Creuzot C, Passemard M, Viau S, et al. (Improvement of dry eye symptoms with

polyunsaturated fatty acids). J Fr Ophtalmol. 29(8), 868-73 (2006).

35. Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. (Efficacy assessment of

Nutrilarm(R), a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary

formulation versus placebo in patients with bilateral treated moderate dry eye

syndrome). J Fr Ophtalmol. 34(7), 448-55 (2011).

36. Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, double-

masked, randomized, controlled trial assessing the effect of oral supplementation of

174